Migraine Pathophysiology: Neurovascular and Inflammatory Mechanisms

Migraine is a complex neurovascular disorder with genetic and environmental triggers. The cascade involves cortical, brainstem, trigeminovascular, and autonomic systems.

Phases & Mechanisms

  1. Premonitory (Prodrome): Hours to days before. Hypothalamic activation → yawning, fatigue, mood change, food craving, neck stiffness. Dopaminergic/hypothalamic dysregulation.
  2. Aura (25–30%): Cortical Spreading Depression (CSD) — wave of neuronal/glial depolarization spreading 2–6 mm/min across cortex. Visual (scotoma, fortification spectra), sensory, motor, speech symptoms. CSD activates trigeminovascular system.
  3. Headache (Attack):
    • Vasodilation: CGRP, PACAP, substance P release from trigeminal afferents → meningeal vasodilation, plasma extravasation, mast cell degranulation.
    • Peripheral Sensitization: Nociceptor activation by inflammatory soup (H⁺, K⁺, prostaglandins, cytokines).
    • Central Sensitization: Trigeminal nucleus caudalis → thalamus → cortex; allodynia (cutaneous sensitivity).
  4. Postdrome: "Migraine hangover" — fatigue, cognitive difficulty, residual sensitivity. Persistent central sensitization.

Key Molecular Players

  • CGRP: Master mediator; released from trigeminal ganglia; targets vascular smooth muscle, mast cells, CNS receptors.
  • PACAP: Co-released with CGRP; independent migraine trigger.
  • Serotonin (5-HT): Modulates trigeminovascular signaling; triptans agonize 5-HT₁B/₁D/₁F.
  • Glutamate, NO, CGRP receptors (CALCRL/RAMP1): Therapeutic targets.

Clinical Translation

  • CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) & gepants (ubrogepant, rimegepant, atogepant) target this pathway.
  • Ditans (lasmiditan) target 5-HT₁F without vasoconstriction.
  • Neuromodulation (sTMS, nVNS, eTNS) disrupts CSD/central sensitization.

Migraine - Related Articles